Login
$RLAY
$17.50 +$0.23 (1.33%) After hours

$RLAY 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027

06 Aug 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback

09 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Relay Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”),

21 May 2026 8-K: Entry into a Material Definitive Agreement

22,916,667 Shares of Common Stock, par value $0.001 per share

19 May 2026 8-K: Regulation FD Disclosure; Other Events

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

05 May 2026 8-K: Results of Operations and Financial Condition

FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer

27 Apr 2026 8-K: Regulation FD Disclosure; Other Events

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

16 Mar 2026 8-K: Regulation FD Disclosure; Other Events

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025

11 Mar 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced

03 Feb 2026 8-K: Regulation FD Disclosure; Other Events

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant

06 Nov 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated

07 Aug 2025 8-K: Results of Operations and Financial Condition

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer

11 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

Cambridge, Mass. – June 11, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today ...

06 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 6, 2025, Relay Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in detail in the Compan...

04 Jun 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

On June 3, 2025, Relay Therapeutics, Inc. (the “Company”) and ARE MA Region No. 58, LLC (the “Landlord”) entered into the Third Amendment (the “Lease Amendment”) to the Lease Agreement (the “Binney Street Lease”), dated November 12, 2019...

05 May 2025 8-K: Results of Operations and Financial Condition

Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025

26 Feb 2025 8-K: Results of Operations and Financial Condition

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer

13 Jan 2025 8-K: Regulation FD Disclosure

J.P. Morgan Conference Presentation January 2025 Exhibit 99.1

11 Dec 2024 8-K: Regulation FD Disclosure; Other Events

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support